



XINTELA AND CATALENT TO CO-DEVELOP BRAIN CANCER THERAPY

Lund, Sweden, 25 October 2018 – Xintela announces today that the company has signed a co-development agreement with the American company Redwood Bioscience Inc., a wholly owned subsidiary of Catalent, Inc., a world leader in antibody-drug conjugate (ADC) technology for cancer therapy. The parties intend to jointly develop an ADC therapeutic product with a first focus on glioblastoma, the most common and most aggressive form of brain tumours in adults. The parties will co-finance the development and jointly work to license the project to a third party for clinical studies and commercialization.

Xintela has previously reported positive results in the company's glioblastoma project using an ADC, based on a specific antibody which was found to target and kill glioblastoma cells in preclinical models. Xintela is now taking the next step in the development together with Catalent, to develop and evaluate ADC candidates for clinical trials. The ADCs will be a combination of Xintela's antibodies with Catalent's SMARTag® ADC technology which has been developed by Redwood Bioscience, Inc.

"This is an important milestone for Xintela's oncology business. Catalent's technology and extensive experience in the ADC area give Xintela the optimal conditions to effectively develop the brain cancer project towards clinical studies and commercialization. The collaboration also gives our oncology business a valuable foundation for the upcoming spin-out of the new company Targinta AB," said Evy Lundgren Åkerlund, CEO Xintela AB.

"Xintela has an exciting oncology target technology and promising preclinical results, which is why we are eager to invest together with Xintela to co-develop a treatment for brain cancer," said David Rabuka, Global Head of R&D, Chemical Biology, Catalent.

About Redwood Bioscience, Inc.

Catalent's proprietary SMARTag® platform provides site-specific protein-modification and linker technologies. It was developed by Redwood Bioscience to enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability. Catalent acquired Redwood Bioscience Inc., in 2014.

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately \$2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.

Press release

Xintela AB (publ)
556780-3480
2018-10-25



Xintela AB (publ)

Evvy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evvy@xintela.se
Medicon Village
223 81 Lund
www.xintela.se

About Xintela

Xintela develops medical products within regenerative medicine and oncology based on its proprietary marker technology, XINMARK®. Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis. Studies on horses have shown that the stem cells are safe and that they have a therapeutic effect on the articular cartilage and the underlying bone after an injury. Xintela has recently established its own GMP-facility to produce stem cells for clinical studies. In the oncology program, XINMARK® is used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against specific tumors with first focus on the aggressive brain tumor glioblastoma. Positive preclinical results from cell studies and animal model have shown that the ADC treatment has a targeting and killing effect on specific tumor cells supporting further development of the company's oncology business. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 25th of October 2018, at 08.30 CEST.